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Purpose. L-Carnosine is a naturally occurring dipeptide which recently gained popularity as an anticataractogenic agent due to its
purported antioxidant activities. There is a paucity of research and conclusive evidence to support such claims. This work offers
compelling data that help clarify the mechanism(s) behind the anticataract properties of L-carnosine. Methods. Direct in vitro
antioxidant free radical scavenging properties were assayed using three different antioxidant (TEAC, CUPRAC, and DPPH) assays.
Indirect in vitro and ex vivo antioxidant assays were studied by measuring glutathione bleaching capacity and total sulfhydryl
(SH) capacity of bovine lens homogenates as well as hydrogen-peroxide-stress assay using human lens epithelial cells. Whole
porcine lenses were incubated in high galactosemedia to study the anticataract effects of L-carnosine.MTT cytotoxicity assays were
conducted on human lens epithelial cells. Results. The results showed that L-carnosine is a highly potent antiglycating agent but
with weak metal chelating and antioxidant properties. There were no significant decreases in lens epithelial cell viability compared
to negative controls. Whole porcine lenses incubated in high galactose media and treated with 20mM L-carnosine showed a
dramatic inhibition of advanced glycation end product formation as evidenced by NBT and boronate affinity chromatography
assays. Conclusion. L-Carnosine offers prospects for investigating new methods of treatment for diabetic cataract and any diseases
that are caused by glycation.
1. Introduction
Cataract is a primary cause of blindness worldwide and is
one of the main causes of visual impairment in the elderly
[1, 2]. The only available treatment is surgical extraction of
the cataractous lens and replacement with an intraocular
implant.This approach though tried and tested is not without
limitations and complications [3, 4] such as endophthalmitis,
retinal detachment, and recurrent posterior capsular opacity
[5]. Cataract surgery remains difficult to access for some
patients in developing countries and given the rise in popula-
tion age, even in developed countries numbers of patients and
consequently waiting lists for surgery are increasing. There is
an underlying need to gain a far better understanding of the
process of cataractogenesis.
Genetics, ageing, and certain chronic diseases such as
diabetes have been recognised as risk factors for cataract [6].
Mechanisms of development of some rarer forms of cataract
are better understood: Galactosaemia and Wilson’s disease
are two genetic diseases associated with lens opacification
and these arise from genetic abnormalities of galactose
metabolism and copper ion transport, respectively [6]. Pro-
cesses underlying themost common forms of cataracts, senile
cataract and diabetic cataract, require further research as the
causes can be multifactorial.
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The unique growth pattern of the human lens and accrual
of new lens fibers onto existing cell layers coupled with no
protein turnover and an age-related depletion of 𝛼-crystallin
chaperone function render the human lens vulnerable to
posttranslational modifications such as phosphorylation,
glycation, deamidation, and aggregation which are caused
by oxidative stress and decline of antioxidant enzymes [7–
9]. These morphological and biochemical changes occur
throughout life, progressing at a very slow rate. Cataract can
also develop as a secondary effect of diabetes.The exactmech-
anism for diabetic cataractogenesis is still not understood but
high levels of plasma glucose that allow glucose molecules to
enter the lens independently are thought to be a major risk
factor, leading to oxidative stress, formation of Schiff ’s base
(a nonenzymatic reaction of glucose with residual primary
amino groups of lens crystallins), and an accumulation of
advanced glycation end products leading to yellow discol-
oration/browning of the lens [10]. It has been reported
recently that there is a direct correlation between plasma
glycated haemoglobin (HbA
1C) levels and diabetic cataract.
An estimate has been made that a 1% reduction of HbA
1C
level is associated with at least 19% reduction of the risk of
developing diabetic cataract [11]. This direct relationship can
be attributed to increasing glucose entry into the lens causing
glycation of lens proteins and antioxidant enzymes with a
concomitant rise in copper levels [12]. Advance glycation end
products have been reported to be able to bind/chelate copper
[13, 14]. Recent reports highlight the importance of chelating
agents in therapies that delay or prevent the formation of
cataracts [15, 16]. Diabetics can develop lens brunescence and
cataract at an earlier age than nondiabetics [17] and they are
at greater risk of developing other postsurgical complications
such as retinopathy, macular oedema, and endophthalmitis
[11]. With increasing numbers of diabetic patients worldwide
and lack of accessibility to surgical treatment of cataract in
many countries, there is a pressing need to find effective non-
surgical treatments that can delay or reverse diabetic cataract.
L-Carnosine is marketed as a prodrug in the form of N-
acetylcarnosine (NAC) eye drops (1%). N-Acetyl carnosine
was found to have a dose-dependent hydrolysis releasing
carnosine into the anterior chamber 15–30 minutes after
instillation onto ocular surface of rabbit lenses [18]. These
eye drops have been considered to be promising with respect
to treatment/prevention of senile cataract in human eyes
and showed good ocular tolerability for up to 6 [18] and 9
[19] months. Topical application of NAC (2% w/w) showed
improvements in lens opacities of canine immature cataracts
or nuclear sclerosis, whereas a marginal reduction was
recorded for mature cataract or cataracts associated with
intraocular inflammation [20]. However, the exact mecha-
nism is still unknown and the Royal College of Ophthalmolo-
gists issued a public statement in August 2008 to indicate that
there is insufficient evidence to support the potential of this
drug for cataract treatment [21].
L-Carnosine is a𝛽-alanyl histidine dipeptide that is endog-
enously present in appreciable amounts in skeletal muscles,
in the lens, and in relatively lower concentrations in other
human tissues [22]. Since its discovery in 1900, numerous
therapeutic benefits have been attributed to the exogenous
administration of L-carnosine; among these are antiageing,
anticancer, and anticataractogenic properties [23–25]. Its
exact physiological function is still unknown; nevertheless,
enhancing buffering capacity of the cell, the recovery from
muscle fatigue, and membrane stabilizing effect are the
main identifiable metabolic roles ascribed to this histidine
dipeptide [22]. Antiglycating, antioxidant, and antiprolif-
erative properties have been also reported for L-carnosine.
Whilst antiglycating properties have been reported in recent
publications [24, 26, 27], the antioxidant properties are
inconclusive and lack sufficient support. Indirect antioxidant
properties were also claimed for L-carnosine in an attempt to
explain how L-carnosine could work clinically.These indirect
antioxidant effects have been reported due to possible in vitro
chelating properties of copper and theremight be possibilities
of inhibiting the initiation of intracellular Fenton’s reaction.
L-Carnosine did not show any oxidation by a common
oxidizing agent such as hydrogen peroxide [28]. This work
is aimed at investigating possible antioxidant, antiglycation,
and copper chelating effects of L-carnosine; further, this
work is interested in studying the cytotoxicity of L-carnosine.
2. Materials and Methods
2.1. Materials. L-Carnosine, aminoguanidine HCl, sodium
azide, nitro blue tetrazolium (NBT), 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES), copper (II) chlo-
ride, sorbitol, ammonium acetate, 𝛼-crystallin from bovine
eye lens, and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra-
zolium bromide (MTT) were purchased from Sigma-
Aldrich, UK. Ascorbic acid, glutathione, and 2,2󸀠-azino-bis-
(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS) were pur-
chased from TCI, Toshima, Tokyo, Japan. 6-Hydroxy-2,5,7,8-
tetramethylchroman-2-carboxylic acid (Trolox) was pur-
chased fromAcrosOrganics,New Jersey,USA. 2,9-Dimethyl-
1,10-phenanthroline (neocuproine) and 5,5󸀠-dithiobis (2-
nitrobenzoic acid) (Ellman’s reagent) were purchased from
Alfa Aesar, Heysham, UK. All other chemicals and reagents
were of analytical grade and used as received.
2.2. Antiglycating Assay. A modification of the method
reported by Matsuda et al. [29] which is based on measuring
the characteristic fluorescence of the advanced glycation
end products (AGEs) was used. In brief, 100mg/mL D-
glucose and 10mg/mL of porcine lens proteins (PLP) were
separately prepared in phosphate buffer (67mM) pH 7.2
containing 0.02% sodium azide as antimicrobial preserva-
tive. Equal volumes of the glucose and PLP solutions were
mixed without and with different concentrations (10mM
and 20mM) of L-carnosine and aminoguanidine (a standard
antiglycating agent). The solutions without L-carnosine and
aminoguanidine acted as positive controls because they do
not contain antiglycating agents. Two negative controls for
L-carnosine and aminoguanidine were used: equal volumes
of glucose (100mg/mL) with different concentrations of
L-carnosine (to eliminate the sacrificing glycation due to
reaction of L-carnosine with glucose) and equal volumes
of PLP (10mg/mL) and aminoguanidine without glucose,
respectively. All samples were incubated for 14 days at 40∘C.
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A volume of 20𝜇L was withdrawn from each sample and
transferred into a 96-well plate. An aliquot of 180 𝜇L of the
phosphate buffer was added to each well and the intensity of
fluorescence was measured at excitation and emission wave-
lengths of 370 nm and 440 nm, respectively, using a TECAN
Infinite M200 Pro plate reader (Ma¨nnedorf, Switzerland).
Percentage inhibition of AGEs formationwas estimated using
AGEs =
𝐼p − (𝐼s − 𝐼c)
𝐼p
∗ 100, (1)
where 𝐼p, 𝐼s, and 𝐼c are fluorescence intensities of the positive
control, sample, and corresponding negative control (S1).
2.3. Antioxidant Assays
2.3.1. Trolox Equivalent Antioxidant Capacity (TEAC) Assay.
This assay is based on quenching of the blue-green colour of
the stable free radical 2,2󸀠-azino-bis(3-ethylbenzothiazoline-
6-sulphonic acid (ABTS∙) by the tested antioxidant. ABTS∙
was generated by the reaction between 7mM ABTS and
2.45mM potassium persulphate in water. The solution was
stored in the dark for 12–16 hours before use. The concen-
tration of the generated ABTS∙ was diluted with phosphate
buffered saline (PBS) pH 7.4 to give a final absorbance of
0.70 ± 0.02 at 734 nm. A concentration of 500𝜇M Trolox
in PBS was prepared and different concentrations of L-
carnosine (up to 20mM) were tested. Additional samples
of ascorbic acid and glutathione were used as validation
samples. These two antioxidants are chosen because they are
endogenously available in aqueous humour and in human
lens. Aliquots of 20𝜇L each of PBS, L-carnosine, ascorbic
acid, glutathione, and Trolox were added to 980 𝜇L of ABTS∙
in Eppendorf tubes and absorbance was measured at 734 nm.
Antioxidant scavenging capacity and TAEC were estimated
through (2) and (3), respectively:
Scavenging Capacitysample = ODcontrol −ODsample, (2)
whereODcontrol andODsample are the optical density of ABTS
∙
after addition of 20𝜇L of PBS and sample, respectively,
TEAC =
Scavenging capacitysample
Scavenging capcitytrolox
. (3)
2.3.2. CUPRAC Antioxidant Assay. Aqueous solutions of
copper (II) chloride (0.01M), ammonium acetate (1M), and
alcoholic (ethanol 96%) solution of neocuproine (7.5mM)
were prepared and mixed in a glass vial in the following
order: 1mL of copper (II), 1mL of neocuproine, 1mL of
ammonium acetate, and 1mL of antioxidant solution [30].
The final mixture was allowed to stand for 30min at room
temperature and absorbance was measured at 450 nm. TEAC
was estimated by dividing OD of the sample by OD of Trolox.
2.3.3. Diphenylpicrylhydrazyl (DPPH) Assay. The DDPH
assay was performed as previously reported [29]. In brief,
equal volumes of DPPH (100 𝜇M) solution and antioxidant
solutions were mixed and absorbance was measured at
517 nm. TEAC for L-carnosine, ascorbic acid, and glutathione
was determined as mentioned above.
2.4. Indirect Antioxidant (Metal-Chelating
Antioxidant) Assays
2.4.1. Bleaching Capacity of Glutathione and Glutathione-
Copper Complex with and without L-Carnosine. Antioxidant
capacities of glutathione alone, glutathione : copper (II)
(1 : 1mol/mol), glutathione : copper (II) : L-carnosine (1 : 1 : 1
and 1 : 1 : 2mol/mol/mol), and glutathione : copper (II) :
EDTA (1 : 1 : 1mol/mol/mol) were measured. The bleaching
capacity (indication of antioxidant capacity) was measured
as mentioned in Section 2.3.1 and determined using (1).
2.4.2. Sulfhydryl Capacity of Glutathione and Glutathione-
Copper Complex with and without L-Carnosine. The sulfhy-
dryl capacity of glutathione alone and glutathione : copper
(II) (1 : 1mol/mol), glutathione : copper (II) : L-carnosine
(1 : 1 : 1 and 1 : 1 : 2mol/mol/mol), and glutathione : copper
(II) : EDTA (1 : 1 : 1mol/mol/mol) was estimated using
Ellman’s reagent [31]. In brief, an aliquot of 250 𝜇L of
Ellman’s reagent 0.4% in Tris-HCl buffer pH 8.4 was added
to a premixed solution of 200𝜇L of crystallin sample and
750𝜇L of Tris-HCl buffer/pH 8.4. The final mixture was
allowed to stand for 10 minutes at room temperature and
the generated yellow colour is measured at 412 nm. A blank
solution was made up of the sample volumes by replacing
200𝜇L crystallins with 200𝜇L Tris-HCl buffer.
2.5. Total Antioxidant Capacity of the Lens Homogenate Incu-
bated with High Levels of Copper (II). Fresh excised bovine
eyes were collected from a local abattoir (ABP Guildford
Slyfield, Surrey, UK) and lenses were extracted within 10
hours of death. Whole lenses were homogenised in a flacon
tube with 12mL of Tris-HCl buffer pH 8.4 containing 0.02%
sodiumazide.Thehomogenatewas centrifuged at 10,000 rpm
for 30minutes at 4∘C.The supernatant was collected to obtain
water soluble (WS) protein fraction [32].
The soluble protein solutions were mixed with aqueous
solution s of copper (II) with and without L-carnosine
(20mM) to form final concentrations of copper (II) 100𝜇M,
10 𝜇M, and 1 𝜇M. Samples of lens crystallins without copper
(II) were used as control. The total sulfhydryl capacity of lens
crystallins was estimated using Ellman’s reagent as mention
in Section 2.4.2.
2.6. Protection of Human Lens Epithelial Cells from H
2
O
2
-
Induced Damage by L-Carnosine. B-3 human lens cells
(ATCC CRL-11421) were grown in accordance with sup-
plier instructions. Briefly, cells were prepared and seeded
out into 96-well plates (Nunclon Delta, Nunc, Netherland)
at approximately 2 × 104 cells/well in Eagle’s Minimum
Essential Medium (EMEM) containing 20% foetal bovine
serum (LGC standards). The cells were allowed to establish
for 48 hours prior to treatment. Media were subsequently
removed and fresh media containing treatments were added;
8 wells were used per treatment condition and all exper-
iments were performed in triplicate. Treatments were two
different concentrations of L-carnosine (10mM or 20mM
final concentration), in the presence or absence (negative
control) of either 1mM or 0.25mM hydrogen peroxide
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(final concentration, positive controls) or untreated for two
durations: 1 hour and 24 hours. After treatment duration,
the media were removed and the cells were washed twice
with 37∘C sterile PBS. The cells were then incubated with
200𝜇L per well of 0.5mg/mL 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) solution in 37∘C
EMEM (LGC standards) with no further additions of serum
for 3 hours at 37∘C. After incubation, the MTT solution
was carefully removed and the wells were washed twice with
sterile PBS. Finally, 200 𝜇L of dimethylsulfoxide (DMSO)
was added to each well to lyse the cells. The cells were then
gently agitated to mix the samples and analyzed on a TECAN
Infinite M200 Pro plate reader using a wavelength of 540 nm.
2.7. Incubation of the Lens in High Sugar Media with and
without L-Carnosine. Fresh excised porcine eyes were col-
lected from a local abattoir and the lens was removed
within less than 24 hours postmortem. Lenses were rinsed
in M199 (Sigma-Aldrich, UK) supplemented with 8% foetal
bovine serum (Sigma-Aldrich, UK) and antibiotics (peni-
cillin/streptomycin, 100 units/mL) (Sigma-Aldrich, UK) and
transferred onto a 6-well plate (Nunclon Delta Surface,
Roskilde, Denmark) containing 10mL of the medium and
incubated for 12 hours at 35∘C/5% CO
2
[33]. Any lenses
showing signs of opacity were discarded. The incubated
lenses were divided into four groups: a negative control
(lenses incubated in the culture medium without galactose),
positive controls (lenses incubated in a medium containing
30mM galactose), and two treated groups containing 10mM
and 20mM of L-carnosine of media supplemented with
30mM galactose. All incubated lenses were incubated at
35∘C/5%CO
2
. Media were changed every 24 hours for 3 days.
Optical integrity, lens transparency, and any opacification
were evaluated visually by looking at a grid through the lens.
2.7.1. Size Exclusion Chromatography and Estimating of 𝛼-
Crystallins. After optical evaluation, lenses were homoge-
nised in 8mL Tris-HCl buffer pH 8.4 containing 0.02%
sodium azide water soluble as described in Section 2.5. Water
soluble (WS) fractions were prepared as mentioned above in
Section 2.5 and separated into fractions based on size using
HPLC (Shimadzu LC-2010AHT, Shimadzu Corporation,
Kyoto, Japan) comprising a quaternary pump, an automatic
sampler, and a UV (280 nm) detector with data acquisition
(Lab solutions software version 5.42 SP5, Shimadzu Corpo-
ration, Japan) and a size exclusion column, Yarra-SEC 4000
(3 𝜇m; 300mm × 7.8mm, Phenomenex Corporation, UK),
maintained at 40∘C. The mobile phase comprised of 50mM
sodium phosphate pH 6.8/0.15M sodium chloride. The iso-
cratic flow rate was 1.0mL/min. Purified 𝛼-crystallin was
purchased from Sigma-Aldrich and used as a reference. The
percentage (%) of soluble 𝛼-crystallin fraction was estimated
as follows:
𝛼-crystallin fraction (%) =
AUCs
AUCc
∗ 100, (4)
where AUCs and AUCc are the area under the size exclusion
(SE) chromatograms for 𝛼-crystallin fraction of the sample
and negative control, respectively, and a representative chro-
matogram is shown as in Supplementary Figure 2 (in Supple-
mentaryMaterial available online at http://dx.doi.org/10.1155/
2016/3240261).
2.7.2. Nitro Blue Tetrazolium (NBT) Assay. This assay is based
on the reducing properties of AGEs or better known as
fructosamine to NBT to formazan (purple colour) under
alkaline conditions [34, 35]. An aliquot of 100𝜇L of WS
fractions was added to 1mL of NBT (0.3M in carbonate
buffer pH 10.35). The mixtures were incubated at 37∘C for
10min, allowed to cool down to room temperature, and
measured spectrophotometrically at 530 nm. Percentage of
glycated crystallins was estimated using
%Glycated crystallins =
ODs −ODc
ODc
∗ 100, (5)
where ODs was the optical density of the positive control or
treated samples and ODc is the optical density of the negative
control.
2.7.3. Boronate Affinity Chromatography for Separation of Gly-
cated Proteins. AnAKTAprotein purification system (AKTA
Purifier, GE Healthcare Bioscience AB, Uppsala, Sweden)
comprising a binary pump and a UV detector with data
acquisition (Unicorn software version 5.11, GE Healthcare
Bioscience AB, Uppsala, Sweden) were used to separate
glycated crystallins from nonglycated crystallins on a TSKgel
Boronate 5PW (10 𝜇m; 75mm × 7.5mm, TOSOH Bioscience
Corporation, Shiba, Japan) maintained at ambient condition.
The binding buffer was comprised of 20mM HEPES (pH
8.5) and 20mMMgCl
2
. The elution buffer was comprised of
20mM HEPES (pH 8.5) and 100mM sorbitol. The isocratic
flow rate used was 1.0mL/min and the injection volume
was fixed at 200𝜇L. Detection was by UV absorbance at a
wavelength of 280 nm.
2.7.4. Cytotoxicity Evaluation (MTT Assay) of L-Carnosine
Using Human Lens Epithelial Cells. B-3 human lens cells
(ATCC CRL-11421) from ATCC were prepared and seeded
out at approximately 2 × 104 cells/well into 96-well plates
(Nunc, Netherland) in Eagle’s Minimum Essential Medium
(EMEM) containing 20% foetal bovine serum (LGC stan-
dards). The cells were allowed to establish for 48 hours
prior to treatment in the 96-well culture plate. Media
were subsequently removed and fresh media containing
treatments (8 wells used per condition) were added. The
treatments were three different concentrations of L-carnosine
1%, 0.5, and 0.1% w/v. The untreated media were used as a
negative control and hydrogen peroxide (300mg/mL) and
benzalkonium chloride (BKC) at a concentration of 0.01%
w/v were used as positive controls. After 3 hours of treatment,
the media were removed and the cells were washed twice
with 37∘C sterile PBS. The cells were then incubated with
200𝜇L per well of 0.5mg/mL 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) solution in 37∘C
EMEM (LGC standards) with no additions for 3 hours
at 37∘C. After incubation, the MTT solution was carefully
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Figure 1: Comparative percentage inhibition of advanced glycation
end products formation recorded for porcine lens crystallins with
two equivalent concentrations (10mM and 20mM) of aminoguani-
dine and two different concentrations of L-carnosine. Results are
presented as mean values ± SD [∗statistically significant; ∗∗not
significant].
removed and themeasurements were performed as described
in Section 2.6.
2.7.5. Statistical Analysis. Statistical analysis was performed
with GraphPad Prism 6 (2014) software, using analysis of
variance (ANOVA) with a Dunnett post hoc test for con-
fidence intervals of 95% with statistical significance set at
𝑃 < 0.05.
3. Results and Discussion
3.1. Antiglycating Assay. Figure 1 shows percentage inhibition
of formation of advanced glycation endproducts (AGEs)with
two different concentrations (10mM and 20mM) of amino-
guanidine (a standard antiglycating agent) and two equiva-
lent concentrations (10mM and 20mM) of L-carnosine. The
results demonstrated that L-carnosine significantly inhibited
glycation compared with aminoguanidine (𝑃 < 0.01) at
equivalent concentration. For example, 80% inhibition was
estimated for L-carnosine 20mM, whereas 60% inhibition
was recorded for an equivalent concentration of aminoguani-
dine.
L-Carnosine has a terminal amino group of the beta-
alaninemoiety with imidazole ring structure that can provide
a more favourable position than 𝜀-amino residues of crys-
tallins for scavenging carbonyls and can be more readily gly-
cated by aldose sugars [24, 26, 27].This also was evident from
fluorescence intensity measurements where the L-carnosine-
glucose mixture showed significantly greater intensity com-
pared with the lens crystallins-glucose (negative control)
mixture (S1).These findings support the idea that L-carnosine
behaves as an antiglycating agent. This effect was concentra-
tion dependent, as approximately 35% of antiglycation capac-
ity increased by doubling the concentration of L-carnosine.
Trolox Ascorbic acid Glutathione L-Carnosine
TEAC
Cuprac assay
DPPH assay
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Figure 2: Trolox equivalent antioxidant capacity of L-carnosine
compared with other endogenous antioxidants using three different
antioxidant assays. Results are presented as mean values ± SD, 𝑛 = 3
[∗statistically significant; ∗∗not significant].
3.2. Antioxidant Assays. The antioxidant capacity of L-
carnosine was evaluated using different commonly used
assays for assessing antioxidant capacity of many drug
molecules, flavonoids, and foods [25, 36]. Figure 2 shows
Trolox equivalent antioxidant capacity for ascorbic acid, glu-
tathione, and L-carnosine using the abovementioned assays.
The results showed that L-carnosine exhibited very weak
direct antioxidant capacity, compared with standard antiox-
idants: glutathione and ascorbic acid. Antioxidant capacity
recorded for L-carnosine by measuring the bleaching of
DPPH (1mM) was only 2.5% compared with the bleaching
capacity of 36% and 39% for the antioxidant bisdiaminotri-
azole compounds, namely, compounds 1 and 1, respectively
[25].
3.3. Indirect Antioxidant (Metal-Chelating Antioxidant)
Assays. Other studies have found indirect antioxidant
capacity for L-carnosine arising from the chelation of copper,
inhibiting Fenton’s reaction and free radical formations [22].
Reduced glutathione (GSH) is an endogenous antioxidant
and it is available in appreciable concentrations in the
human lens [36]. Decline of glutathione levels in the lens
has been found to be associated with oxidation and disulfide
cross-linking of lens crystallins and cataract formation [6].
This study explored whether there is any possible indirect
antioxidant activity for L-carnosine by potentiating glutathi-
one system. This hypothesis was studied by two different
methods: firstly; measuring the fading (bleaching) of the
blue-green colour of ABTS∙ due to reduction to ABTS by
GSH and secondly assessing the sulfhydryl capacity of GSH
under different conditions as shown in Figures 3 and 4.
Figure 3 shows the bleaching capacity of GSH under
different conditions (GSH alone, GSHwith L-carnosine, GSH
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Figure 3: Bleaching (of the coloured free radicals ABTS∙) capacity
ofGSHalone andGSHwith equimolar ratios of copper, L-carnosine,
and EDTA. Results are presented as mean values ± SD, 𝑛 = 3
[∗statistically significant; ∗∗not significant].
with copper (II), GSH with copper (II), and L-carnosine
at two different molar ratios and GSH, with copper (II)
and EDTA). GSH shows the highest bleaching capacity
(decolourising the free radicals ABTS∙) given that it is a
potent antioxidant. Addition of L-carnosine did not show
any significant potentiation of the bleaching capacity of GSH,
indicating the lack of antioxidant capacity of L-carnosine
which supports the results found with antioxidant assays.
Addition of copper significantly reduced the antioxidant
capacity of GSH (𝑃 < 0.05); this is likely to be caused by
the chelating properties of GSH rather than the redox reac-
tion [37]. Glutathione has been reported to have molecular
chaperone properties for copper in the cytoplasm of the lens
epithelial cells [37]. Consistent with this report, addition of
a stronger chelating agent (EDTA) regenerates the natural
bleaching capacity of glutathione (Figure 3).
Figure 4 shows sulfhydryl capacity of glutathione and glu-
tathione treated with the six different conditions as described
above. Significant depletion of sulfhydryl groups of GSH was
recorded with the GSH samples containing copper alone
and copper and L-carnosine, whereas sulfhydryl capacity was
restored to normal levels after the addition of EDTA but not
with L-carnosine. These results are similar to those reported
with bleaching capacity (Figure 3) and this is also in support
to the abovementioned results. These findings support the
idea that L-carnosine does not show indirect antioxidant
capacity.
3.4. Protection of Human Lens Epithelial Cells from H
2
O
2
-
Induced Damage by L-Carnosine. These two concentrations
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Figure 4: Sulfhydryl capacity of glutathione alone, glutathione with
L-carnosine, glutathione with copper, and glutathione and copper
with different molar ratios of L-carnosine and EDTA. Results are
presented asmean values± SD, 𝑛 = 3 [∗statistically significant; ∗∗not
significant].
(10mM and 20mM) of L-carnosine used to investigate
whether this substance could protect cultured human lens
epithelial cells fromH
2
O
2
were selected based on preliminary
screening of different concentrations. The cells subjected to
these two concentrations showed inhibited proliferation and
significant oxidative damage compared with negative control
cells. The possible protective mechanism of L-carnosine
(10mM and 20mM) was studied over two different time
points of 1 and 24 hours corresponding to any possible
protection from either direct free radical scavenging or gene
induction effect due to possible H
2
O
2
-induced damage to
DNA, respectively (Figure 5).
The results showed that L-carnosine had no protective
effect on cells from the oxidant activity of hydrogen peroxide.
These findings are in line with the in vitro antioxidant assays
as well as other results that have been recently reported
elsewhere [25].
3.5. Total Antioxidant Capacity of the Lens Homogenate Incu-
bated with High Levels of Copper. Total sulfhydryl capacity
of lens has been an indirect indicator of oxidative stress and
damage to lens crystallins [32]. Copper can catalyze free
radical formation and reactive oxygen species (ROS) [22, 38].
In this study, copper was added to the lens homogenate to
induce oxidative stress via Fenton’s reaction.
Figure 6 shows total sulfhydryl capacity of lens
homogenate incubated with copper and L-carnosine for 6
days at 35∘C.The presence of copper showed a concentration
dependent depletion of sulfhydryl capacity; the addition of
L-carnosine did not show any significant protection.
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Figure 5: Human lens epithelial cell viability after exposure to two
concentrations of H
2
O
2
with and without two different concentra-
tions of L-carnosine. Results are presented as mean values ± SD,
𝑛 = 3 [∗statistically significant; ∗∗not significant].
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Figure 6: Total sulfhydryl capacity of lens homogenate incu-
bated with different concentrations of copper with and without
L-carnosine. Results are presented as mean values ± SD, 𝑛 = 3
[∗statistically significant].
3.6. Lens Incubation in High Sugar Media. Induction of
experimental cataract is an important approach used to gain
a better understanding of cataract formation and to help
develop potential therapeutic treatments that could delay or
reverse cataractogenesis. To date, there is no in vivo or in
vitro experimental model that can simulate human senile
cataract in terms of the time required and physiological
concentrations of cataract inducers because this form of
cataract develops over many decades period with more than
a single causal factor. Cataracts that occur as secondary man-
ifestations of diabetes, however, can develop at faster rates.
Numerous in vivo and in vitro models have been studied [39,
40]. Galactose is approximately 2.5 times more favourable as
a substrate for aldose reductase than glucose and can cause
substantially higher levels of osmotic stress and generate
a larger number of free radicals, compared with glucose
[41]. Galactose is also a significantly more active glycating
agent than glucose. Galactose is available in 3.5 times higher
concentration of the acyclic open (reactive) form, that is, with
glucose at pH 7.5 [42]. Galactose was used in this study to
induce cataract formation in vitro in excised bovine lenses.
On the third day of incubation, harvested lenses from
negative control, positive control, and treated groups were
placed on a grid to investigate optical quality. Lenses
incubated in a high galactose medium showed marked
yellowing/browning of lens cortex, compared with con-
trol lenses incubated in a medium free of galactose. Lens
brunescence is a consequence of glycation and likely to
mimic the processes that underlie diabetic cataract [13]. The
lens brunescence was partially inhibited by supplementing
the media with 10mM L-carnosine; lenses incubated with
20mM L-carnosine demonstrated a level of transmittance
that appeared to be similar to that of negative controls. This
concentration (20mM)has been reported to be theminimum
effective concertation of L-carnosine in the aqueous humour
to produce anticataractogenic effects [22].
Approximately 15% ofWS 𝛼-crystallins became insoluble
or were degraded into lower molecular weight fractions as
a result of lens incubation in the high galactose medium.
By comparison, only 10% and 5% of WS 𝛼-crystallins were
lost from lenses incubated in high galactose media with 10
and 20mML-carnosine, respectively (Figure 7).These results
suggest that glycation may be linked with a loss of chaperone
activity of 𝛼-crystallin. This concurs with previous work
that found 𝛼-crystallins from goats lenses incubated with
fructose and glucose-6-phosphate had a significant decrease
in chaperone activity due to nonenzymatic glycosylation of𝛼-
crystallins [43]. It is worth noting that the galactose treatment
did not show any notable changes in profiles of the WS
fractions from size exclusion chromatography (Figure S2).
This is because the study investigated early stage glycation
which does not produce sufficient cross-linking that would
manifest as large aggregates that would alter the size exclusion
chromatographic profiles. The more sensitive test for these
early stage changes is evident in affinity chromatography as
shown in Figure 8.
The percentage of lens protein glycation recorded for
the positive control was at least 30%, whereas treatment
with L-carnosine showed a significant inhibition in the
percentage of glycated proteins. Figure 8 shows separation
of glycated crystallins from nonglycated crystallins using a
boronate affinity chromatographic column for three different
lenses incubated in media alone (negative control), positive
control (media supplemented with 30mM galactose), and
the treated group with L-carnosine (20mM). The negative
control lenses showed the smallest fraction of glycated
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Figure 7: Porcine lenses incubated in negative control medium and in high galactose medium, high galactose with 10mM L-carnosine, and
high galactose with 20mML-carnosine (a), percentage of 𝛼-crystallin remaining after lens incubationmeasured for negative control, positive
and treated lenses with L-carnosine (10mM and 20mM) (b), and percentage of glycated proteins for positive control and treated lenses with
L-carnosine (10 and 20mM) (c). Results are presented as mean values ± SD, 𝑛 = 3 [∗statistically significant; ∗∗not significant].
crystallins which represent physiologically normal glycated
crystallins, whereas a sharp and intense glycated peak was
recorded for positive control lenses at the expense of the
nonglycated crystallin fraction. L-Carnosine treated lenses
showed marked suppression of the glycated peak compared
with the positive control. The glycated peaks recorded for
L-carnosine-treated groups represent a combination of the
physiological glycation fraction and a residual fraction of
glycated proteins arising from the presence of galactose.
These findings suggest a chaperone function of L-carnosine
in protecting lens crystallins by inhibiting the formation
of AGEs and accord with previous findings that show L-
carnosine is a potent antiglycating agent [26].
3.7. Cytotoxicity Evaluation (MTTAssay) of L-CarnosineUsing
Human Lens Epithelial Cells. Table 1 shows estimated cell
viability after a 3-hour exposure to different treatments. The
positive controls (BKC and H
2
O
2
) have been shown to be
cytotoxic over the duration tested in this study [44–46].
Three different concentrations of L-carnosine were examined
for any cytotoxicity; these concentrations were low concen-
tration 0.1% w/v (4.4mM), 0.5% w/v (22mM) as a middle
drug concentration, and the highest concentration of 1% w/v
(44.2mM). The latter concentration is used commercially
in the form of prodrug eye drops of N-acetyl L-carnosine.
This concentration showed a significant cytotoxic (𝑃 <
0.05) effect; however, such a concentration is unlikely to
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Figure 8: Boronate affinity chromatograms of nonglycated and glycated lens crystallins.
Table 1: Immortalised human lens epithelial cell viability (%)
after 3-hour exposure to the test substances employing MTT assay.
Results are presented as mean values ± SD, 𝑛 = 3.
Test substance Lens cellviability (%)
Statistical
significance to the
medium
Media (negative control) 100 —
BKC (positive control) 17 ± 3.2 𝑃 < 0.05
H
2
O
2
(positive control) 16 ± 3.6 𝑃 < 0.05
L-Carnosine (1%) 76 ± 13 𝑃 < 0.05
L-Carnosine (0.5%) 81.5 ± 9.2 𝑃 > 0.05
L-Carnosine (0.1%) 100 ± 10 𝑃 > 0.05
reach the lens due to excessive drug loss and tear dynamics
associated with topical ocular drug administration on the
surface of the eye [47]. Whilst there were slight decreases
in cell viability after exposure to lower concentrations 0.5%
and 0.1%w/v, thesewere not statistically significant compared
to the negative control (𝑃 > 0.05). It is worth nothing
that BKC (which is cytotoxic when used over comparable
duration) is used routinely as a preservative in ophthalmic
eye drops at a concentration of 0.01% w/v; the duration of
exposure of the eye to BKC when applied in eye drops is
considerably shorter.These findings indicate that L-carnosine
in the concentrations and for the durations tested does not
demonstrate cytotoxicity in human lens epithelial cells.
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4. Conclusion
L-Carnosine showed a potent antiglycation effect, in vitro,
in cultured porcine lenses and human lens epithelial cells
models. However, there is no evidence to support either
direct or indirect antioxidant activities. Furthermore, using
L-carnosine when there is no evidence of diabetes or of
conditions that may induce such effects may cause harm
to the redox glutathione system of the lens. These findings
warrant investigations on the potential of L-carnosine as a
therapeutic agent for delaying the development of diabetic
cataract by mopping up excess glucose in the aqueous
humour without deleterious effects on lens crystallins.
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